Clinical Trials List
2023-03-06 - 2030-12-31
Phase II
Recruiting4
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2024/02/21
Investigators and Locations
Co-Principal Investigator
- 周旭桓 無
- Mengting Peng 無
- 阮昱翔 無
- Shin-Cheh Chen 無
- 沈士哲 無
- 徐執中 無
- Chi-Chang Yu 無
- Wen-Chi Shen 無
- Wen-Ling Kuo 無
- Chan-Keng Yang 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- MING-YANG WANG 無
- 張端瑩 無
- 羅喬 無
- WEI-LI MA 無
- 黃柏翔 無
- 李佳真 無
- 陳怡君 無
- 林季宏 無
- Wei-Wu Chen 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳彥蓁 無
- Chun-Yu Liu 無
- 邱仁輝 無
- Ta-Chung Chao 無
- Jiun-I Lai 無
- 馮晉榮 無
- Yi-Fang Tsai 無
- 林燕淑 無
- Chi-Cheng Huang 無
- 賴亦貞 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
約20 participants
-
Global
160 participants
